Founded in 2011, XenoGesis now has clients across six continents and has experienced consistent growth since day one. The increase in international clients is the direct result of the business’ growth strategy to develop overseas markets.
XenoGesis specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modelling & simulation for human PK and dose prediction and prides itself on working closely with clients to help them to achieve their drug discovery goals using a consultative approach.
In the financial year ending March 2017, 33% of all revenue came from overseas clients with the largest increases in revenue from clients in Europe and the USA.
Richard Weaver, founder and Managing Director of XenoGesis, commented, “This growth in exports has exceeded our expectations. It highlights the attractive proposition the UK has to offer; whether it is a lack of expertise locally in overseas markets or the wealth of scientific knowledge and expertise in the UK, we are definitely seeing a marked increase in international businesses turning to us for advice and support.”
He continued, “We expect this trend to continue with more and more clients coming to us from overseas for our high quality, consultative and flexible approach. Furthermore, the UK may become increasingly financially attractive in light of the current economic and political climate.”
